Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Condition:   Interstitial Lung Disease Interventions:   Drug: efzofitimod 450 mg;   Drug: efzofitimod 270 mg;   Drug: Placebo Sponsor:   aTyr Pharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials